MRace Implant: A first look at fixing the mitral valve to reduce regurgitation
Official title: Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant Brazil (EXPLORE MRace - GE)
Run by Polares Medical SA · NCT07796659 · Data updated 2026-11-12
This single-arm study tests whether the MRace Implant and Delivery System can safely place a prosthesis to reduce severe mitral regurgitation in high-risk patients who may not be good candidates for open-heart surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Polares Medical SA Industry-sponsored |
| Locations | 4 sites (Tbilisi and 3 other locations) |
| Status | Recruiting |
| Started | May 23, 2022 |
| Main results expected | December 2032 |
| Study ends | December 2032 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT07796659 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18+ with greater than moderate MR (3+ or higher) who are high surgical risk but deemed operable by a local heart team.
✕Probably not a fit
Patients with severe tricuspid or aortic disease or those with certain anatomical factors may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early feasibility study will enroll up to 100 adults with at least moderate-to-severe mitral regurgitation who are high surgical risk. It uses a transcatheter approach to implant a posterior leaflet augmentation prosthesis via a transvenous/transseptal route, aiming to improve valve coaptation. The primary goal is to assess safety and feasibility, with follow-up extending to five years to gather preliminary performance data. The study is conducted at four centers in Georgia and Israel and is structured as a registry without a control group. Patients will receive regular post-procedure evaluations to monitor MR reduction and valve function.
Why it matters
Potential benefit: If successful, patients may experience reduced mitral regurgitation and potentially improved symptoms and quality of life without open-heart surgery.
How similar studies have gone: Prior edge-to-edge repair approaches have shown benefit in select high-risk patients; this MRace strategy is an exploratory, novel approach with limited prior clinical success data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years of age or older 2. Greater than moderate mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure 3. Patient must present with an STS Score less than 10% 4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications), but operable, as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure 5. New York Heart Association (NYHA) Functional Class III or IV 6. Patient willing to participate in study and provide signed IRB/EC-approved informed consent 7. Treating physician and patient agree that patient is able to return for all required post-procedure follow-up visits Exclusion Criteria: 1. Severe tricuspid regurgitation 2. Severe aortic stenosis or insufficiency 3. Severe mitral annulus calcification 4. Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification 5. Implanted vena cava filter 6. Femoral veins with severe angulation and calcification 7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan 8. Active infection or endocarditis 9. Previous mitral valve surgery 10. Prior orthotopic heart transplantation 11. Pulmonary artery systolic hypertension \> 70mmHg 12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus 13. Left ventricular ejection fraction (LVEF) \< 20% 14. Implant or revision of any pacing device \< 30 days prior to intervention 15. Symptomatic coronary artery disease treated \< 30 days prior to study procedure 16. Myocardial infarction requiring intervention \< 30 days prior to study procedure 17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis 18. Active peptic ulcer or upper gastrointestinal bleeding \< 90 days prior to study procedure 19. Stroke \< 180 days prior to study procedure 20. Severe renal insufficiency (creatinine \> 3.0 mg/dL) or Subject requiring dialysis 21. Cardiogenic shock at time of enrollment 22. Hemodynamic instability requiring inotropic support or mechanical heart assistance 23. Concurrent medical condition with a life expectancy of less than 2 years 24. Pregnancy or breastfeeding at time of enrollment 25. History of bleeding diathesis or coagulopathy or leukopenia (WBC \< 3,000 mcL) or acute anemia (Hb \< 9 g/dL) or thrombocytopenia (platelets \< 50,000 cells mcL) 26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated 27. Emergency situations 28. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments 29. Company employees or their immediate family members 30. Subject is under guardianship 31. Subject is participating in another clinical study for which follow-up is currently ongoing.
Where it's running
-
Israeli-Georgian Medical Research Clinic Healthycore
Tbilisi, Georgia Recruiting -
LLC "Emergency Cardilogy Center by Acad. G. Chapidze"
Tbilisi, Georgia Recruiting -
Ltd Tbilisi Heart and Vascular Clinic
Tbilisi, Georgia Recruiting -
Ltd Tbilisi Heart Centre
Tbilisi, Georgia Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mitral Valve Calcification Imaging with TrueVue 3D Light Rendering
This study tests how well three-dimensional transesophageal echocardiography with TrueVue transillumination detects mitral valve calcifications compared with CT in adults.
-
Tracking progression and consequences of heart valve disease
This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.
-
Surgical implantation of a polymer prosthetic mitral or aortic valve
This will test a surgically implanted polymer heart valve to see if it is safe and works well for adults who need mitral or aortic valve replacement.
-
Abbott Cephea registry for mitral valve disease
Collects clinical information on adults with symptomatic mitral valve disease to see how correcting the valve with the Cephea system affects outcomes for patients who might be candidates for transcatheter mitral valve replacement.
-
Using the CoolCryo System to treat Atrial Fibrillation during Mitral Valve Surgery
This study is testing whether the CoolCryo system can safely help people with atrial fibrillation feel better during mitral valve surgery.
-
Left atrial shunt to help after mitral valve surgery
This study tests whether making a small opening between the left and right atria during mitral valve repair can relieve high left atrial pressure for adults with primary mitral regurgitation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.